ArticleInternational journal of clinical and experimental medicine2011
Post-transcriptional regulation of PDGFα-receptor in O-2A progenitor cells.
Article in International journal of clinical and experimental medicine, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
latelet-derived growth factor alpha-receptor (PDGFαR) mediated signaling plays a key role in the development of glial cells of the central nervous system. In vivo and in vitro studies show that PDGFαR is actively expressed in proliferative and motile oligodendrocyte type-2 astrocyte (O-2A) glial progenitor cells. However, PDGFαR expression is barely detectable in mature glial cells. The exact mechanism underlying the loss of PDGFαR expression is unknown. In this study, we employed a rat brain-derived O-2A glial progenitor cell line, CG4 as a culture model to investigate signals capable of inhibiting PDGFαR gene expression. PDGFαR mRNA levels decreased significantly as CG4 cells differentiated into both oligodendrocyte and astrocyte lineages. We showed that inhibition of PDGFαR expression was promoted by prostaglandin E2 via protein kinase A activation. Both cAMP analogs (db-cAMP and 8'bromo-cAMP) and adenylate cyclase activator (forskolin) were potent suppressors of PDGFαR expression in CG4 cells. This inhibitory effect resulted from an increased destabilization of PDGFαR mRNA instead of a decreased PDGFαR gene transcription. Importantly, db-cAMP failed to reduce PDGFαR mRNA levels in several PDGFαR over-expressing human glioma cell lines. Together, these results suggest that cAMP-dependent pathway played a key regulatory role in controlling PDGFαR mRNA levels during normal glial development, and that a breakdown in the cross talk between cAMP and PDGF pathways may underlie the uncontrolled proliferation and immature differentiation state in the glial tumors.
Indexed as
Identifiers
22140595PMC3228579W340700064What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.